MedPath

LB Pharmaceuticals, Inc.

LB Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2015-09-01
Employees
11
Market Cap
-
Website
http://www.lbpharma.us

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2023-12-21
Last Posted Date
2025-04-29
Lead Sponsor
LB Pharmaceuticals Inc.
Target Recruit Count
359
Registration Number
NCT06179108
Locations
🇺🇸

Pillar Clinical Research, Richardson, Texas, United States

🇺🇸

Woodland Internation Research Group, Little Rock, Arkansas, United States

🇺🇸

Woodland Research Northwest, Rogers, Arkansas, United States

and more 20 locations

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2020-10-19
Last Posted Date
2022-05-04
Lead Sponsor
LB Pharmaceuticals Inc.
Target Recruit Count
16
Registration Number
NCT04588129
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2019-12-05
Last Posted Date
2020-12-10
Lead Sponsor
LB Pharmaceuticals Inc.
Target Recruit Count
64
Registration Number
NCT04187560
Locations
🇺🇸

Medpace Clinical Pharmacology LLC, Cincinnati, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.